Aminoglycoside prescription, therapeutic monitoring and nephrotoxicity at a University Hospital in Saudi Arabia

Journal of Chemotherapy

Volumn 8, Issue 4, 1996, Pages 278-283

  Eltahawy, A T A E ^a   Bahnassy, A A E ^a,b  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Amikacin; Aminoglycoside toxicity; Dose monitoring; Gentamicin; Nephrotoxicity; Risk factors

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN;

ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PATIENT MONITORING; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; RISK FACTOR; SAUDI ARABIA; TREATMENT OUTCOME;

EID: 0029782610     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1996.8.4.278     Document Type: Article

References (21)

1. Pancoast SJ. Aminoglycoside antibiotics in clinical usage. Med Clin North Am 1988; 72: 581-612.
2. Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302: 1106-1109.
3. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Leitman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 198-4; 100: 352-357.
4. Lawyers CL, Moore RD, Lerner SA, Smith CR. A model for predicting nephrotoxicity in patients treated with amino-glycosides. J Infect Dis 1986; 153: 1062-1068.
5. Esienberg JM, Koffer H, Click HA, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987; 107: 900-909.
6. Editorial. Aminoglycoside toxicity. Lancet 1986; II 670-671.
7. Shrimpton SB, Milmoe M, Wilson APR et al. Audit of prescription and assay of aminoglycosides in a UK teaching hospital. J Antimicrob Chemother 1993; 31: 599-606.
8. Zaske DE, Sawchuck RJ, Gerding DN, Strate RG. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976; 16: 824-828.
9. Zaske DE, Cipolle RJ, Strate RJ. Gentamicin dosage requirements:Wide interpatient variation in 242 Surgery patients with normal renal function. Surgery 1980; 87: 164-169.
10. Carr MR, Dick SP, Bordley J, Bertino JS. Gentamicin dosing requirements in patients with acute pancreatitis. Surgery 1988; 103: 533-537.
11. Levy J, Smith AL, Koup JR, Williams-Warren J,Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a controlled study. J Padiatr 1984; 105: 117-124.
12. Pancorbo S, Comply C, Hessier J. Comparison of gentamicin and tobramycin nephrotoxicity in patients receiving individualized - Pharmacokinetics dosing regimens. Biopharm Drug Dispos 1982; 3: 83-88.
13. Humes HD, Weinberg JM, Knauss TC. Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity. Am J Kidney Dis 1982; 2: 5-29.
14. British National Formulary. 5.1.4. Aminoglycosides. In British National Formulary, no. 23; March. 1992, p.210. British Medical Association and Royal Pharmaceutical Society of Great Britain, London.
15. Mann HJ, Fuhs DH, Awang R, Ndemo FA, Cerva FA. Altered aminoglycoside Pharmacokinetics in critically ill patients with sepsis. Clin Pharm 1987; 6: 148-163.
16. Noone PT, Parsons MC, Pattison JR, Stack RS, Garfield-Davis D, Hughes K. Experience in monitoring gentamicin therapy during treatment of serious Gram-negative sepsis. Br J Med 1974; 1: 477-481.
17. Spectpr R, Park GD, Johnson GF, Vessel ES. Therapeutic drug monitoring. Clin Pharmacol Ther 1988; 43: 345-353.
18. McInnes GT. The value of therapeutic drug monitoring to the practicing physicians: an hypothesis in need of testing. Br J Clin Pharmacol 1989; 27: 281-284.
19. Cunha BA. Amnoglycosides in urology. Urology 1990; 36:1-14.
20. McCormack JP, Jewesson PJ. A critical evaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis 1992; 14(1): 320-339.
21. Rotheram EB. Clinical response and peak concentrations of aminoglycosides [letter]. J Infect Dis 1988; 157: 159.